You are here: Home » Companies » News
Business Standard

Biocon gets nod to market psoriasis drug in India

Drugs Controller General allows marketing of Bangalore-developed Itolizumab

BS Reporter  |  Bangalore 

Publicly-held biotechnology major Biocon announced on Tuesday that it has received marketing authorisation from the Drugs Controller General of India (DCGI) for its novel biologic Itolizumab, anti CD6 molecule, for the treatment of chronic plaque psoriasis.

Itolizumab is a first-in-class therapy and the second novel biologic developed by Biocon at Asia’s largest biotech hub in Bangalore.

This approval paves the way for the launch of Biocon’s Alzumab in the country later this year. Alzumab is a differentiated biologic drug with a better safety profile compared to other approved biologic therapies, given its low opportunistic infection rates. A novel biologic indicated for the treatment of moderate-to-severe psoriasis, Alzumab will be marketed by Biocon’s immunotherapy division. Alzumab will be manufactured and formulated as an infusion drug at Biocon’s biopharma manufacturing facility at Biocon Park, Bangalore.

TREND SETTER
  • Itolizumab is a first-in-class therapy
  • A 52-week clinical study conducted in India indicated an excellent safety profile
  • It is the second novel biologic developed by Biocon at Asia’s largest biotech hub, in Bangalore
  • The approval paves the way for the launch of Biocon’s Alzumab in the country later this year
  • Kiran Mazumdar-Shaw (pictured), CMD of Biocon, called the approval a defining moment for Biocon

Commenting on this development, Kiran Mazumdar-Shaw, chairman and managing director of Biocon, said, “This is our second novel biologic that we have developed in India, BioMab EGFR, an anti-cancer monoclonal antibody, being the first. This approval paves the way for us to extend clinical development for other indications like rheumatoid arthritis, multiple sclerosis and vitiligo.”

She added that the company will file an IND (investigational new drug) in the US shortly “to embark on a global clinical development plan”. She termed the approval for Itolizumab “a defining moment for Biocon”.

Alzumab is expected to provide a safe and effective treatment option for psoriasis, a socially debilitating disease affecting two-three per cent of India’s population. The global psoriasis market size is estimated to cross $8 billion by 2016.

Biocon’s share price dropped 2.3 per cent on the National Stock Exchange to close at Rs 294.70 per share on Tuesday.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, January 09 2013. 00:53 IST
RECOMMENDED FOR YOU
.